{"id":571761,"date":"2021-10-28T21:50:01","date_gmt":"2021-10-28T21:50:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=571761"},"modified":"2021-10-28T21:50:01","modified_gmt":"2021-10-28T21:50:01","slug":"psoriasis-clinical-and-nonclinical-studies-therapeutic-pipeline-analysis-and-emerging-therapies-key-companies-dermavant-ucb-eli-lilly-pfizer-arbor-pharma-boehringer-ingelheim-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/psoriasis-clinical-and-nonclinical-studies-therapeutic-pipeline-analysis-and-emerging-therapies-key-companies-dermavant-ucb-eli-lilly-pfizer-arbor-pharma-boehringer-ingelheim-and-others_571761.html","title":{"rendered":"Psoriasis Clinical and Non-Clinical Studies, Therapeutic Pipeline Analysis, and Emerging Therapies | Key Companies &#8211; Dermavant, UCB, Eli Lilly, Pfizer, Arbor Pharma, Boehringer Ingelheim, and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Psoriasis Clinical and Non-Clinical Studies, Therapeutic Pipeline Analysis, and Emerging Therapies | Key Companies - Dermavant, UCB, Eli Lilly, Pfizer, Arbor Pharma, Boehringer Ingelheim, and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Psoriasis Clinical and Non-Clinical Studies, Therapeutic Pipeline Analysis, and Emerging Therapies | Key Companies - Dermavant, UCB, Eli Lilly, Pfizer, Arbor Pharma, Boehringer Ingelheim, and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Psoriasis Pipeline Insight, 2021&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Psoriasis Market.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Psoriasis Pipeline<\/strong> report embraces in-depth commercial and clinical assessment of the Psoriasis pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, <strong>Psoriasis collaborations<\/strong>, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Psoriasis Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/93bf8633e55c3e771b27ce2ffecd85f1.jpg\" alt=\"Psoriasis Pipeline Analysis\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/psoriasis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Psoriasis Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the <strong>treatment of Psoriasis<\/strong> with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Psoriasis Treatment.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Psoriasis key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Psoriasis Drugs<\/strong> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the <strong>Psoriasis market<\/strong>.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/psoriasis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Psoriasis Therapeutics Landscape<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The dynamics of the Psoriasis market is anticipated to change in the coming years owing to the expected launch of emerging therapies.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Several companies across the globe are thoroughly working toward the development of new treatments and devices which are expected to change the current market scenario for Psoriasis.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key companies in the Psoriasis Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">UCB<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Eli Lilly and Company<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Boehringer Ingelheim<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Akros Pharma Inc.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Kadmon Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pfizer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Arbor Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Dr. Reddy&rsquo;s Laboratories&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Dermavant<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And several others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Psoriasis Therapies covered in the report includes:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bimekizumab&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mirikizumab&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">BI 730357&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">JTE-451<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">KD025<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">PF-06826647<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">XP23829&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Tapinarof&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample Pages @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/psoriasis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">Psoriasis Emerging Therapies and Key Companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Report Highlights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">A better understanding of disease pathogenesis contributing to the development of <strong>novel therapeutics for Psoriasis<\/strong>.&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In the coming years, the Psoriasis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The companies and academics are working to assess challenges and seek opportunities that could influence <strong>Psoriasis Research &amp; Development<\/strong>. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">A detailed portfolio of major pharma players who are involved in fueling the Psoriasis treatment market. Several potential <strong>therapies for Psoriasis<\/strong> are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Psoriasis market size in the coming years.&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Our in-depth analysis of the <strong>Psoriasis pipeline assets<\/strong> (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Download&nbsp;Sample Pages @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/psoriasis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">Psoriasis Therapeutics Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Psoriasis&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Psoriasis Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Psoriasis &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Psoriasis Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Psoriasis Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Psoriasis Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Psoriasis Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Psoriasis Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Psoriasis Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Psoriasis Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Psoriasis Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Psoriasis Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Visit to get the sample report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/psoriasis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/psoriasis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=psoriasis-clinical-and-nonclinical-studies-therapeutic-pipeline-analysis-and-emerging-therapies-key-companies-dermavant-ucb-eli-lilly-pfizer-arbor-pharma-boehringer-ingelheim-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=psoriasis-clinical-and-nonclinical-studies-therapeutic-pipeline-analysis-and-emerging-therapies-key-companies-dermavant-ucb-eli-lilly-pfizer-arbor-pharma-boehringer-ingelheim-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP Psoriasis Pipeline Insight, 2021&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Psoriasis Market. The Psoriasis Pipeline report embraces in-depth commercial and clinical assessment of the Psoriasis pipeline &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/psoriasis-clinical-and-nonclinical-studies-therapeutic-pipeline-analysis-and-emerging-therapies-key-companies-dermavant-ucb-eli-lilly-pfizer-arbor-pharma-boehringer-ingelheim-and-others_571761.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-571761","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/571761","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=571761"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/571761\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=571761"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=571761"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=571761"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}